JW THERAP-B(02126.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 50.43 million, loss narrowed by 81.13% YoY

NewTimeSpace News: August 27, 2026, JW THERAP-B(02126.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 111.35 million, increased by 4.71% YoY; Net Profit stood at loss of CNY 50.43 million, loss narrowed by 81.13% YoY; Profit Attributable to Shareholders stood at loss of CNY 50.43 million, loss narrowed by 81.13% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.12.

In terms of profitability, JW THERAP-B Gross Profit changed from CNY 65.12 million in the same period last year to CNY 57.71 million in the current period, decreased by CNY 7.41 million; gross profit margin changed from 61.23% in the same period last year to 51.82% in the current period, decreased by 9.41 percentage points; net profit changed from loss of CNY 267.27 million in the same period last year to loss of CNY 50.43 million in the current period, increased by CNY 216.84 million; net profit margin changed from -251.32% in the same period last year to -45.28% in the current period, increased by 206.04 percentage points. 

In terms of earnings quality, JW THERAP-B Operating Profit changed from loss of CNY 273.44 million in the same period last year to loss of CNY 50.66 million in the current period, increased by CNY 222.79 million; Operating Profit Margin changed from -257.12% in the same period last year to -45.49% in the current period, increased by 211.63 percentage points. 

In terms of financial soundness, JW THERAP-B Debt-to-Asset Ratio changed from 35.99% in the same period last year to 45.7% in the current period, increased by 9.71 percentage points; Total Equity changed from CNY 908.608 million in the same period last year to CNY 452.4 million in the current period, decreased by CNY 456.21 million; Current Liabilities changed from CNY 470.35 million in the same period last year to CNY 315.06 million in the current period, decreased by CNY 155.29 million; Quick Ratio changed from 1.45 in the same period last year to 1.27 in the current period, decreased by 0.18 percentage points. 

In terms of R&D investment focus, JW THERAP-B R&D Expenses changed from CNY 92.04 million in the same period last year to CNY 49.82 million in the current period, decreased by CNY 42.22 million; R&D to Total Revenue Ratio changed from 86.55% in the same period last year to 44.74% in the current period, decreased by 41.81 percentage points. 

By the close of trading on August 27, 2026, JW THERAP-B(02126) saw a gain of 4.65% in its share price, closing at HKD 2.25. The full-day turnover stood at HKD 3.05 million, with the latest market capitalization at HKD 937.64 million.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.